Ikarian Capital’s Epizyme, Inc EPZM Stock Holding History

Ikarian Capital’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-29,080	Closed	-$347K	–	263
2020 Q3	$347K	Buy	+29,080	New	+$390K	0.03%	148

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KXA

KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Ikarian Capital's EPZM Position: Q4 2020 in Review

Ikarian Capital sold out of Epizyme, Inc (EPZM) in Q4 2020, closing a stake of 29,080 shares — an estimated $347K sold.

Ikarian Capital first reported a position in EPZM in Q3 2020 and held it in 1 quarter. The position peaked at $347K in Q3 2020. 137 funds tracked by Wall St. Rank hold EPZM as of Q4 2020.

Ikarian Capital reported no remaining Epizyme, Inc position as of Q4 2020 after selling out during the quarter.
Ikarian Capital sold 29,080 Epizyme, Inc shares in Q4 2020, an estimated $347K.
Ikarian Capital first reported a position in Epizyme, Inc in Q3 2020 and held it in 1 quarter.
Ikarian Capital's Epizyme, Inc position peaked at $347K in Q3 2020.
137 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2020.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.